

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/914,451	09/914,451 12/20/2001		Jesper Z. Haeggstrom	PVZ-006US 4167	
959	7590	02/23/2006		EXAMINER	
LAHIVE &		TIELD	TALAVERA, MIGUEL A		
BOSTON, MA 02109				ART UNIT	PAPER NUMBER
·				1656	

DATE MAILED: 02/23/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/914,451	HAEGGSTROM ET AL.				
Office Action Summary	Examiner	Art Unit				
	Miguel A. Talavera	1656				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
<ul> <li>1) ⊠ Responsive to communication(s) filed on Octobe</li> <li>2a) ☐ This action is FINAL.</li> <li>2b) ☑ This</li> <li>3) ☐ Since this application is in condition for alloware closed in accordance with the practice under E</li> </ul>	action is non-final. nce except for formal matters, pro					
Disposition of Claims						
4)  Claim(s) 36-59 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) 39-59 are subject to restriction and/or	vn from consideration.					
Application Papers						
<ul> <li>9) The specification is objected to by the Examiner.</li> <li>10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).</li> <li>11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.</li> </ul>						
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of: <ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No</li> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:					

Application/Control Number: 09/914,451 Page 2

Art Unit: 1656

**DETAILED ACTION** 

Status of Application

1. In response to the previous Office action, a restriction requirement (mailed on July 14,

2005), Applicants filed a response on October 14, 2005 that cancelled claims 1-35 and added

new claims 36-59. Upon review of newly submitted claims, the following requirement was

deemed necessary:

Lack of Unity

2. Lack of unity is required under 35 U.S.C. § 121 and 372. This application contains the

following inventions or groups of inventions, which are not so linked as to form a single general

inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a

single invention to which the claims must be restricted.

Group I, claim(s) 36-59, drawn to the special technical feature of a method for designing a drug

involving molecular modeling.

Group II, claim(s) 36-59, drawn to the special technical feature of a method for designing a drug

involving direct structure based design.

Group III, claim(s) 36-59, drawn to the special technical feature of a method for designing a drug

involving combinatorial chemistry.

Art Unit: 1656

3. The technical feature linking the inventions of Groups I-III is a molecular structure. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reason(s):

According to PTC Rule 13.2, unity of invention exists only where the shared same or corresponding technical feature is a contribution over the prior art. Claim 36 is not limited to the use of a molecular structure from an LTA<sub>4</sub> hydrolase protein having the structural coordinates as set forth in Table 9 in practicing the claimed methods. Instead, claim 36 has been interpreted in accordance to M.P.E.P. § 2111 as encompassing a method of using any molecular structure. Thus, claim 36 encompasses a method to design a drug utilizing any molecular structure, i.e., "functionally equivalent part, derivative or conformational analogue thereof", by molecular modeling. Since Kuntz *et al.* (Science, vol.257, pp. 1078-1082, 1992) discloses computer strategies for the design of novel inhibitors, the technical feature for Groups I-III does make it a contribution over the prior art.

- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/914,451

Art Unit: 1656

6. Claim 37 will be examined only to the extent the claim reads on the elected invention.

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Miguel A. Talavera whose telephone number is (571)272-3354. The examiner can normally be reached on M-F, 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen M. Kerr can be reached on (571)272-0931. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David J. Steadman, Ph.D. Primary Examinep

Miguel A. Talavera, Ph.D. February 21, 2006